LANSOPRAZOLE

[A substituted benzimidazole prodrug with selective and irreversible proton pump inhibitor activity. Lansoprazole prodrug is converted to an active sulfonamide derivative in the acidic environment of the gastric parietal cell; the sulfonamide derivative binds to the gastric proton pump H+/K+ ATPase and forms a stable disulfide bond with the sulfhydryl group near the potassium-binding site on the luminal side, resulting in inactivation of the ATPase and a reduction in gastric acid secretion. This agent does not have anticholinergic or histamine H2 -receptor antagonistic properties. ( NCI )]

UMLS (NCI) C0050940

Organic Chemical
Pharmacologic Substance

Relation/PAR: 5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole
[GA303] H.PYLORI AGENTS
[GA309] ANTIULCER AGENTS, OTHER
[GA900] GASTRIC MEDICATIONS, OTHER

Relation/CHD: LANSOPRAZOLE 15 MG
LANSOPRAZOLE 30 MG
LANSOPRAZOLE 28 X 30 MG

home

MeSH

top

MEDINDEX.AM